| Bid | 16.91 |
| Market Cap | 1.06B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -20.8 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 17.2 |
| Volume | 86,428 |
| Avg. Volume (20D) | 168,288 |
| Open | 18.10 |
| Previous Close | 18.02 |
| Day's Range | 17.21 - 18.28 |
| 52-Week Range | 6.59 - 22.69 |
| Beta | undefined |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed i...
3 weeks ago · businesswire.com
Pulse Biosciences, Inc. Announces Election to Exercise Company WarrantsHAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano...
2 months ago · businesswire.com
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial ResultsMIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-P...
